A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATEMPT
- 18 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 18 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated